Delaware | 77-0154833 | |
(State or other jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. | Results of Operations and Financial Condition |
Item 9.01. | Financial Statements and Exhibits |
Exhibit No. | Description | |
99.1 | Press release dated October 24, 2018 describing the Company's results for its third quarter ended September 30, 2018 and other financial information. |
NATUS MEDICAL INCORPORATED (Registrant) | ||||||
Dated: October 24, 2018 | By: | /s/ Drew Davies | ||||
Executive Vice President and Chief Financial Officer |
• | Reports record third quarter revenue of $130.6 million |
• | Reports third quarter GAAP loss per share of $0.17 and non-GAAP earnings per share of $0.40 |
• | Updates annual revenue and earnings guidance for 2018 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) | |||||||||||||||
(in thousands, except per share amounts) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||||||
Revenue | $ | 130,638 | $ | 122,643 | $ | 389,900 | $ | 369,531 | |||||||
Cost of revenue | 51,583 | 47,112 | 159,849 | 158,615 | |||||||||||
Intangibles amortization | 1,930 | 1,290 | 6,235 | 3,789 | |||||||||||
Gross profit | 77,125 | 74,241 | 223,816 | 207,127 | |||||||||||
Gross profit margin | 59.0 | % | 60.5 | % | 57.4 | % | 56.1 | % | |||||||
Operating expenses: | |||||||||||||||
Marketing and selling | 33,200 | 32,537 | 102,474 | 95,106 | |||||||||||
Research and development | 15,127 | 11,632 | 46,186 | 38,098 | |||||||||||
General and administrative | 15,799 | 17,329 | 56,967 | 57,501 | |||||||||||
Intangibles amortization | 4,477 | 3,882 | 13,434 | 11,841 | |||||||||||
Restructuring | 11,432 | 321 | 14,182 | 914 | |||||||||||
Total operating expenses | 80,035 | 65,701 | 233,243 | 203,460 | |||||||||||
Income (loss) from operations | (2,910 | ) | 8,540 | (9,427 | ) | 3,667 | |||||||||
Interest expense | (1,644 | ) | (1,025 | ) | (5,240 | ) | (3,287 | ) | |||||||
Other income | 918 | 1,175 | 296 | 2,019 | |||||||||||
Income (loss) before tax | (3,636 | ) | 8,690 | (14,371 | ) | 2,399 | |||||||||
Provision for income tax expense (benefit) | 1,940 | 17,203 | (3,069 | ) | 15,597 | ||||||||||
Net loss | $ | (5,576 | ) | $ | (8,513 | ) | $ | (11,302 | ) | $ | (13,198 | ) | |||
Loss per share: | |||||||||||||||
Basic | $ | (0.17 | ) | $ | (0.26 | ) | $ | (0.34 | ) | $ | (0.41 | ) | |||
Diluted | $ | (0.17 | ) | $ | (0.26 | ) | $ | (0.34 | ) | $ | (0.41 | ) | |||
Weighted-average shares: | |||||||||||||||
Basic | 33,321 | 32,593 | 32,982 | 32,536 | |||||||||||
Diluted | 33,321 | 32,593 | 32,982 | 32,536 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) | |||||||||||
(in thousands) | |||||||||||
September 30, | June 30, | December 31, | |||||||||
2018 | 2018 | 2017 | |||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and investments | $ | 54,440 | $ | 54,908 | $ | 88,950 | |||||
Accounts receivable | 121,113 | 122,971 | 126,809 | ||||||||
Inventories | 80,586 | 76,630 | 71,529 | ||||||||
Other current assets | 30,843 | 32,224 | 18,340 | ||||||||
Total current assets | 286,982 | 286,733 | 305,628 | ||||||||
Property and equipment | 21,564 | 21,645 | 22,071 | ||||||||
Goodwill and intangible assets | 318,618 | 326,109 | 345,580 | ||||||||
Deferred income tax | 10,135 | 10,296 | 10,709 | ||||||||
Other assets | 16,746 | 18,855 | 25,931 | ||||||||
Total assets | $ | 654,045 | $ | 663,638 | $ | 709,919 | |||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 20,595 | $ | 24,053 | $ | 25,242 | |||||
Accrued liabilities | 52,015 | 54,874 | 51,738 | ||||||||
Deferred revenue | 16,816 | 16,892 | 15,157 | ||||||||
Total current liabilities | 89,426 | 95,819 | 92,137 | ||||||||
Long-term liabilities: | |||||||||||
Long-term debt | 114,426 | 119,379 | 154,283 | ||||||||
Deferred income tax | 18,896 | 18,936 | 19,407 | ||||||||
Other long-term liabilities | 21,338 | 21,970 | 21,995 | ||||||||
Total liabilities | 244,086 | 256,104 | 287,822 | ||||||||
Total stockholders’ equity | 409,959 | 407,534 | 422,097 | ||||||||
Total liabilities and stockholders’ equity | $ | 654,045 | $ | 663,638 | $ | 709,919 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) | |||||||
(in thousands) | |||||||
Three Months Ended | |||||||
September 30, 2018 | September 30, 2017 | ||||||
Operating activities: | |||||||
Net loss | $ | (5,576 | ) | $ | (8,513 | ) | |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||
Provision for losses on accounts receivable | 1,782 | 1,632 | |||||
Depreciation and amortization | 8,958 | 7,040 | |||||
Loss on disposal of property and equipment | 250 | 20 | |||||
Warranty reserve | (902 | ) | (401 | ) | |||
Share-based compensation | 9,814 | 2,248 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 891 | (4,762 | ) | ||||
Inventories | (2,700 | ) | 699 | ||||
Prepaid expenses and other assets | 743 | 719 | |||||
Accounts payable | (3,435 | ) | (8,734 | ) | |||
Accrued liabilities | (2,446 | ) | 1,967 | ||||
Deferred revenue | 58 | 998 | |||||
Deferred income tax | 191 | 11,021 | |||||
Net cash provided by operating activities | 7,628 | 3,934 | |||||
Investing activities: | |||||||
Acquisition of businesses, net of cash acquired | — | 4,844 | |||||
Purchases of property and equipment | (1,740 | ) | (1,285 | ) | |||
Purchase of intangible assets | (339 | ) | — | ||||
Net cash provided by (used in) investing activities | (2,079 | ) | 3,559 | ||||
Financing activities: | |||||||
Proceeds from stock option exercises and Employee Stock Purchase Program purchases | 5,423 | 174 | |||||
Taxes paid related to net share settlement of equity awards | (4,847 | ) | (549 | ) | |||
Deferred debt issuance costs | — | (316 | ) | ||||
Contingent consideration earn-out | — | (446 | ) | ||||
Proceeds from borrowings | — | 50,000 | |||||
Payments on borrowings | (5,000 | ) | (5,000 | ) | |||
Net cash provided by (used in) financing activities | (4,424 | ) | 43,863 | ||||
Exchange rate changes effect on cash and cash equivalents | (1,593 | ) | 746 | ||||
Net Increase (decrease) in cash and cash equivalents | (468 | ) | 52,102 | ||||
Cash and cash equivalents, beginning of period | 54,908 | 80,303 | |||||
Cash and cash equivalents, end of period | $ | 54,440 | $ | 132,405 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||||||
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited) | |||||||||||||||
(in thousands, except per share amounts) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||||||
GAAP based results: | |||||||||||||||
Income before provision for income tax | $ | (3,636 | ) | $ | 8,690 | $ | (14,371 | ) | $ | 2,399 | |||||
Non-GAAP adjustments: | |||||||||||||||
Intangibles amortization - (COGS) | 1,930 | 1,290 | 6,235 | 3,789 | |||||||||||
Recall accrual and remediation efforts (COGS) | (1,198 | ) | (714 | ) | 1,375 | 3,945 | |||||||||
Restructuring and other non-recurring costs (COGS) | 846 | — | 873 | 1,684 | |||||||||||
Direct costs of acquisitions (COGS) | 402 | 76 | 3,882 | 4,446 | |||||||||||
Intangibles amortization - (OPEX) | 4,483 | 3,882 | 13,439 | 11,841 | |||||||||||
Direct costs of acquisitions (M&S) | 14 | (302 | ) | 423 | (338 | ) | |||||||||
Recall accrual and remediation efforts (R&D) | 1,288 | 1,469 | 4,875 | 6,571 | |||||||||||
Direct costs of acquisitions (R&D) | 50 | 24 | 235 | 24 | |||||||||||
Restructuring and other non-recurring costs (OPEX) | 12,904 | 321 | 18,108 | 5,401 | |||||||||||
Direct costs of acquisitions (G&A) | 502 | 1,457 | 3,682 | 2,370 | |||||||||||
Restructuring and other non-recurring costs (OI) | — | — | 366 | — | |||||||||||
Direct costs of acquisitions (OI) | — | — | — | 48 | |||||||||||
Extraordinary annual meeting expenses | 15 | — | 2,230 | — | |||||||||||
Extraordinary patent litigation | — | 306 | 996 | 1,642 | |||||||||||
Non-GAAP income before provision for income tax | 17,600 | 16,499 | 42,348 | 43,822 | |||||||||||
Income tax expense, as adjusted | $ | 4,227 | $ | 3,380 | $ | 9,357 | $ | 9,672 | |||||||
Non-GAAP net income | $ | 13,373 | $ | 13,119 | $ | 32,991 | $ | 34,150 | |||||||
Non-GAAP earnings per share: | |||||||||||||||
Basic | $ | 0.40 | $ | 0.40 | $ | 1.00 | $ | 1.05 | |||||||
Diluted | $ | 0.40 | $ | 0.40 | $ | 0.99 | $ | 1.03 | |||||||
Weighted-average shares used to compute | |||||||||||||||
Basic non-GAAP earnings per share | 33,321 | 32,593 | 32,982 | 32,536 | |||||||||||
Diluted non-GAAP earnings per share | 33,551 | 33,100 | 33,388 | 33,086 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited) | |||||||||||
(in thousands, except per share amounts) | |||||||||||
Three Months Ended | Nine Months Ended | ||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||
GAAP Gross Profit | 77,125 | 74,241 | 223,816 | 207,127 | |||||||
Amortization of intangibles | 1,930 | 1,290 | 6,235 | 3,789 | |||||||
Direct cost of acquisitions | 402 | 76 | 3,882 | 4,446 | |||||||
Recall accrual and remediation efforts | (1,198 | ) | (714 | ) | 1,375 | 3,945 | |||||
Restructuring and other non-recurring costs | 846 | — | 873 | 1,684 | |||||||
Non-GAAP Gross Profit | 79,105 | 74,893 | 236,181 | 220,991 | |||||||
Non-GAAP Gross Margin | 60.6 | % | 61.1 | % | 60.6 | % | 59.8 | % | |||
GAAP Operating Profit | (2,910 | ) | 8,540 | (9,427 | ) | 3,667 | |||||
Amortization of intangibles | 6,413 | 5,172 | 19,674 | 15,630 | |||||||
Recall accrual and remediation efforts | 90 | 755 | 6,250 | 10,516 | |||||||
Extraordinary patent litigation | — | 306 | 996 | 1,642 | |||||||
Restructuring and other non-recurring costs | 13,750 | 321 | 18,981 | 7,085 | |||||||
Direct cost of acquisitions | 968 | 1,255 | 8,222 | 6,502 | |||||||
Extraordinary annual meeting expenses | 15 | — | 2,230 | — | |||||||
Non-GAAP Operating Profit | 18,326 | 16,349 | 46,926 | 45,042 | |||||||
Non-GAAP Operating Margin | 14.0 | % | 13.3 | % | 12.0 | % | 12.2 | % | |||
GAAP Provision for income tax expense (benefit) | 1,940 | 17,203 | (3,069 | ) | 15,597 | ||||||
Effect of accumulated change of pretax income | (15,493 | ) | (1,942 | ) | (4,701 | ) | 5,099 | ||||
Effect of change in annual expected tax rate | 15,704 | (1,126 | ) | 14,120 | (473 | ) | |||||
Repatriation tax adjustment | — | — | 101 | — | |||||||
Stock-based compensation adjustment | 791 | — | 1,621 | — | |||||||
Valuation Allowance for GAAP purposes | 1,285 | (10,755 | ) | 1,285 | (10,755 | ) | |||||
Effect on acquisition cost | — | — | — | 204 | |||||||
Non-GAAP Income tax expense | 4,227 | 3,380 | 9,357 | 9,672 | |||||||
Quarter Ended | Year Ended | ||||||||||
December 31, 2018 | December 31, 2018 | ||||||||||
GAAP EPS Guidance | $0.26 - $0.29 | ($0.07) - ($0.04) | |||||||||
Amortization of Intangibles | 0.20 | 0.79 | |||||||||
Restructuring and other non-recurring costs | 0.03 | 0.67 | |||||||||
Litigation | — | 0.03 | |||||||||
Recall Accrual and Remediation Efforts | 0.03 | 0.22 | |||||||||
Direct cost of acquisitions | 0.02 | 0.26 | |||||||||
Tax effect | (0.06) | (0.43) | |||||||||
Non-GAAP EPS Guidance | $0.48 - $0.51 | $1.47 - $1.50 |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||||||
GROSS MARGIN BY BUSINESS UNIT (unaudited) | |||||||||||||||
(in thousands) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||||||
Neuro: | |||||||||||||||
Revenue | $ | 69,790 | $ | 59,368 | $ | 206,162 | $ | 174,955 | |||||||
Cost of revenue | 25,275 | 21,222 | 79,628 | 65,011 | |||||||||||
Intangibles amortization | 1,042 | 470 | 3,507 | 1,369 | |||||||||||
Gross profit | 43,473 | 37,676 | 123,027 | 108,575 | |||||||||||
Gross profit margin | 62.3 | % | 63.5 | % | 59.7 | % | 62.1 | % | |||||||
Newborn care: | |||||||||||||||
Revenue | $ | 31,210 | $ | 33,666 | $ | 91,188 | $ | 108,408 | |||||||
Cost of revenue | 13,044 | 12,848 | 38,223 | 52,248 | |||||||||||
Intangibles amortization | 119 | 126 | 358 | 338 | |||||||||||
Gross profit | 18,047 | 20,692 | 52,607 | 55,822 | |||||||||||
Gross profit margin | 57.8 | % | 61.5 | % | 57.7 | % | 51.5 | % | |||||||
Otometrics: | |||||||||||||||
Revenue | $ | 29,638 | $ | 29,609 | $ | 92,550 | $ | 86,168 | |||||||
Cost of revenue | 13,264 | 13,042 | 41,998 | 41,356 | |||||||||||
Intangibles amortization | 769 | 694 | 2,370 | 2,082 | |||||||||||
Gross profit | 15,605 | 15,873 | 48,182 | 42,730 | |||||||||||
Gross profit margin | 52.7 | % | 53.6 | % | 52.1 | % | 49.6 | % | |||||||
Consolidated: | |||||||||||||||
Revenue | $ | 130,638 | $ | 122,643 | $ | 389,900 | $ | 369,531 | |||||||
Cost of revenue | 51,583 | 47,112 | 159,849 | 158,615 | |||||||||||
Intangibles amortization | 1,930 | 1,290 | 6,235 | 3,789 | |||||||||||
Gross profit | 77,125 | 74,241 | 223,816 | 207,127 | |||||||||||
Gross profit margin | 59.0 | % | 60.5 | % | 57.4 | % | 56.1 | % |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||
RECONCILIATION OF NON-GAAP GROSS MARGIN BY BUSINESS UNIT (unaudited) | |||||||||||
(in thousands) | |||||||||||
Three Months Ended | Nine Months Ended | ||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||
Neuro: | |||||||||||
GAAP Gross Profit | 43,473 | 37,676 | 123,027 | 108,575 | |||||||
Amortization of intangibles | 1,042 | 469 | 3,507 | 1,364 | |||||||
Acquisition charges | 402 | — | 3,832 | — | |||||||
Recall accrual and remediation efforts | — | — | — | 1,781 | |||||||
Non-GAAP Gross Profit | 44,917 | 38,145 | 130,366 | 111,720 | |||||||
Non-GAAP Gross Margin | 64.4 | % | 64.3 | % | 63.2 | % | 63.9 | % | |||
Newborn care: | |||||||||||
GAAP Gross Profit | 18,047 | 20,692 | 52,607 | 55,822 | |||||||
Amortization of intangibles | 119 | 128 | 358 | 345 | |||||||
Recall accrual and remediation efforts | (1,198 | ) | (714 | ) | 1,375 | 2,164 | |||||
Restructuring and other non-recurring costs | 846 | 848 | 1,684 | ||||||||
Non-GAAP Gross Profit | 17,814 | 20,106 | 55,188 | 60,015 | |||||||
Non-GAAP Gross Margin | 57.1 | % | 59.7 | % | 60.5 | % | 55.4 | % | |||
Otometrics: | |||||||||||
GAAP Gross Profit | 15,605 | 15,873 | 48,182 | 42,730 | |||||||
Amortization of intangibles | 769 | 693 | 2,370 | 2,080 | |||||||
Acquisition charges | — | 76 | 50 | 4,446 | |||||||
Restructuring and other non-recurring costs | — | — | 25 | — | |||||||
Non-GAAP Gross Profit | 16,374 | 16,642 | 50,627 | 49,256 | |||||||
Non-GAAP Gross Margin | 55.2 | % | 56.2 | % | 54.7 | % | 57.2 | % | |||
Consolidated: | |||||||||||
GAAP Gross Profit | 77,125 | 74,241 | 223,816 | 207,127 | |||||||
Amortization of intangibles | 1,930 | 1,290 | 6,235 | 3,789 | |||||||
Acquisition charges | 402 | 76 | 3,882 | 4,446 | |||||||
Recall accrual and remediation efforts | (1,198 | ) | (714 | ) | 1,375 | 3,945 | |||||
Restructuring and other non-recurring costs | 846 | — | 873 | 1,684 | |||||||
Non-GAAP Gross Profit | 79,105 | 74,893 | 236,181 | 220,991 | |||||||
Non-GAAP Gross Margin | 60.6 | % | 61.1 | % | 60.6 | % | 59.8 | % |
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES | |||||||||||
GEOGRAPHIC REVENUE (unaudited) | |||||||||||
(in thousands) | |||||||||||
Three Months Ended | Nine Months Ended | ||||||||||
September 30, 2018 | September 30, 2017 | September 30, 2018 | September 30, 2017 | ||||||||
Consolidated Revenue: | |||||||||||
United States | 77,980 | 68,697 | 222,135 | 200,506 | |||||||
International | 52,658 | 53,946 | 167,765 | 169,025 | |||||||
Totals | 130,638 | 122,643 | 389,900 | 369,531 | |||||||
United States | 60 | % | 56 | % | 57 | % | 54 | % | |||
International | 40 | % | 44 | % | 43 | % | 46 | % | |||
Totals | 100 | % | 100 | % | 100 | % | 100 | % |
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end